In the first study of its kind, investigators have found that alemtuzumab works better than or as well as either basiliximab or antithymocyte globulin for induction therapy in renal transplant recipients. John Schieszer reports in today’s Medical Minute that these findings are very good news in terms of treatment costs.

Continue Reading